Call for Abstract

7th International Conference on Antimicrobial and Antibacterial Agents, will be organized around the theme “”

Antimicrobial Congress 2024 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Antimicrobial Congress 2024

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Antimicrobials refer to agents that either destroy or hinder the growth of microorganisms. These medicines are typically categorized based on the types of microorganisms they target. For instance, antibiotics are designed to eliminate or inhibit bacterial growth, while antifungals are formulated to combat fungi. Furthermore, antimicrobials can be classified according to their mode of action: those that impede microbial growth are termed Biostatic agents, whereas those that directly kill microbes are known as Microbicidal agents.

Novel antibiotics and antimicrobial agents represent a critical frontier in the ongoing battle against infectious diseases and antimicrobial resistance. These innovative compounds and therapeutic approaches hold promise in addressing the challenges posed by multidrug-resistant pathogens. From synthetic molecules with enhanced efficacy to natural compounds with unique antimicrobial properties, researchers are continually exploring new avenues to discover and develop novel antibiotics. Additionally, advancements in antimicrobial peptides, bacteriophages, and immunotherapy are reshaping the landscape of antimicrobial agents.


Pharmacokinetics and pharmacodynamics (PK/PD) play a crucial role in understanding the behavior and efficacy of antimicrobial drugs within the body. Pharmacokinetics refers to how the body processes a drug, including absorption, distribution, metabolism, and excretion. Pharmacodynamics, on the other hand, focuses on how a drug interacts with its target microorganism and exerts its antimicrobial effect. In the context of antimicrobials, studying PK/PD parameters helps optimize dosing regimens to achieve optimal drug concentrations at the site of infection while minimizing toxicity and the risk of antimicrobial resistance.


Mechanisms of antibiotic resistance refer to the various ways in which bacteria evolve and adapt to become resistant to the effects of antibiotics. One common mechanism is through the alteration of bacterial targets, where mutations or modifications in cellular structures make antibiotics less effective. Another mechanism involves the production of enzymes, such as beta-lactamases, that degrade or inactivate antibiotics before they can exert their antibacterial effects. Additionally, bacteria can develop efflux pumps that actively remove antibiotics from inside the cell, reducing their concentration and efficacy.


Nanotechnology has revolutionized antimicrobial drug delivery by offering precise and targeted therapeutic solutions. Nanoparticles, with their unique properties and size range, enable controlled release of antimicrobial agents at the infection site, enhancing efficacy while reducing side effects. This technology allows for improved bioavailability, prolonged drug circulation, and protection of drugs from degradation, thus overcoming many challenges associated with conventional drug delivery systems. Additionally, nanocarriers can be functionalized with ligands for specific targeting of pathogens or infected cells, making them highly versatile and adaptable.


Antimicrobial use in veterinary medicine plays a critical role in maintaining animal health, preventing and treating infectious diseases, and ensuring food safety. Veterinarians carefully prescribe antimicrobials to livestock, pets, and other animals to control bacterial, viral, fungal, and parasitic infections. Responsible antimicrobial use involves proper diagnosis, selection of appropriate drugs, dosage optimization, and adherence to treatment protocols to minimize the development of antimicrobial resistance.


Vaccines and immunotherapies play a critical role in preventing and treating infectious diseases and cancers. Vaccines are designed to stimulate the body's immune system to recognize and fight specific pathogens, thereby preventing infection or reducing its severity. Immunotherapies, on the other hand, harness the power of the immune system to target and destroy cancer cells or pathogens. These therapies can include immune checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, and cytokine therapies.


Antiviral therapies and drug development play a crucial role in combating viral infections and improving public health. With the constant threat of emerging viral pathogens and the challenges posed by viral outbreaks such as influenza, HIV/AIDS, and COVID-19, the development of effective antiviral treatments is of paramount importance. Antiviral therapies encompass a wide range of strategies, including direct-acting antivirals, immunomodulators, and combination therapies. Advances in drug development have led to the discovery of novel antiviral agents targeting specific viral enzymes, viral entry mechanisms, and viral replication processes.


Combination therapy for antimicrobial resistance involves the use of two or more antimicrobials to treat infections that are resistant to single drugs. This approach is designed to enhance efficacy, reduce the development of resistance, and improve patient outcomes. By targeting multiple pathways or mechanisms of action, combination therapy can overcome resistance mechanisms employed by pathogens. It is particularly effective against multidrug-resistant bacteria and infections that are difficult to treat with conventional antibiotics alone.


Strategies for fungal infections encompass a multidimensional approach aimed at prevention, diagnosis, and treatment. Prevention strategies include maintaining proper hygiene, particularly in healthcare settings, and minimizing exposure to fungal spores. Diagnostic strategies involve accurate and timely identification of fungal pathogens through microbiological cultures, molecular techniques, and imaging studies. Treatment strategies often depend on the type and severity of the fungal infection but may include antifungals such as azoles, echinocandins, and polyenes.

Drug-resistant bacteria pose significant challenges in healthcare settings, as they can render conventional antibiotics ineffective, leading to treatment failures and increased mortality rates. One of the main challenges is the overuse and misuse of antibiotics, contributing to the development of resistance. Additionally, inadequate infection control measures and lack of access to effective antimicrobials in certain regions exacerbate the problem. To combat drug-resistant bacteria, a multifaceted approach is essential. This includes promoting antimicrobial stewardship programs to optimize antibiotic use, investing in research and development of new antibiotics